Kopelman J N, Duff P, Read J A
Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, Washington.
J Reprod Med. 1989 Mar;34(3):225-30.
We compared oral ritodrine and terbutaline for the prevention of recurrent preterm labor. Women between 20 and 35 weeks' gestation who successfully completed a course of intravenous tocolysis were eligible for inclusion. One hundred two patients were randomized to oral ritodrine (20 mg every four hours) or oral terbutaline (5 mg every four hours). The groups showed no significant differences with respect to recognized risk factors for preterm labor or prognostic factors for the failure of tocolysis. Initial treatment failures occurred more frequently in the ritodrine group (nine vs. two, P = .0527). There were no statistically significant differences in the treatment results or frequency of side effects. We conclude that ritodrine appears to be less effective than terbutaline upon the initiation of oral therapy and that oral ritodrine and terbutaline are equivalent in safety and efficacy when used on a long-term basis for preventing recurrent preterm labor.
我们比较了口服利托君和特布他林预防复发性早产的效果。妊娠20至35周且成功完成静脉内宫缩抑制治疗疗程的女性符合纳入标准。102例患者被随机分为口服利托君组(每4小时20毫克)或口服特布他林组(每4小时5毫克)。两组在早产公认风险因素或宫缩抑制失败的预后因素方面无显著差异。利托君组初始治疗失败的发生率更高(9例对2例,P = 0.0527)。治疗结果或副作用发生率无统计学显著差异。我们得出结论,在开始口服治疗时,利托君似乎比特布他林效果差,并且口服利托君和特布他林在长期用于预防复发性早产时安全性和有效性相当。